Jun-Jie Zhang1, Fei Ye1, Kai Xu2, Jing Kan1, Ling Tao3, Teguh Santoso4, Muhammad Munawar5, Damras Tresukosol6, Li Li7, Imad Sheiban8, Feng Li9, Nai-Liang Tian10, Alfredo E Rodríguez11, Chotnoparatpat Paiboon12, Francesco Lavarra13, Shu Lu14, Kitigon Vichairuangthum15, Hesong Zeng16, Lianglong Chen17, Ruiyan Zhang18, Shiqin Ding19, Fengtang Gao20, Zening Jin21, Lang Hong22, Likun Ma23, Shangyu Wen24, Xueming Wu25, Song Yang26, Wei-Hsian Yin27, Jun Zhang28, Yan Wang29, Yonghong Zheng30, Lei Zhou31, Limin Zhou32, Yuansheng Zhu33, Tan Xu34, Xin Wang35, Hong Qu36, Yulong Tian37, Song Lin38, Lijun Liu39, Qinghua Lu40, Qihua Li41, Bo Li42, Qing Jiang43, Leng Han44, Guojun Gan45, Mengyue Yu46, Defeng Pan47, Zhenglu Shang48, Yanfang Zhao49, Zhizhong Liu50, Ye Yuan51, Cynthia Chen52, Gregg W Stone53, Yaling Han2, Shao-Liang Chen1,54. 1. Division of Cardiology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. 2. Division of Cardiology, General Hospital of Northern Theater Command, Shenyang, China. 3. Division of Cardiology, Xijing Hospital, 4th Military Medical University, Xi'an, China. 4. Division of Cardiology, Medistra Hospital, University of Indonesia Medical School, Jakarta, Indonesia. 5. Division of Cardiology, Binawaluya Cardiac Center, Jakarta, Indonesia. 6. Division of Cardiology, Medicine Siriraj Hospital, Bangkok, Thailand. 7. Division of Cardiology, Guangzhou Red Cross Hospital, Guangzhou, China. 8. Division of Cardiology, Pederzoli Hospital-Peschiera del Garda, Verona, Italy. 9. Division of Cardiology, Oriental General Hospital, Huainan, China. 10. Division of Cardiology, Nanjing Heart Center, Nanjing, China. 11. Division of Cardiology, Otamendi Hospital, Buenos Aires, Argentina. 12. Division of Cardiology, Bangkok General Hospital, Bangkok, Thailand. 13. Division of Cardiology, Jilin Cardiovascular Hospital, Changchun, China. 14. Division of Cardiology, Taicang 1st People's Hospital, Taicang, China. 15. Division of Cardiology, Bangplee Hospital, Bangkok, Thailand. 16. Division of Cardiology, Wuhan Tongji Hospital, United Medical University, Wuhan, China. 17. Division of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China. 18. Division of Cardiology, Shanghai Ruijin Hospital, Shanghai Communication University, Shanghai, China. 19. Division of Cardiology, Xinhua Hospital, Huainan, China. 20. Division of Cardiology, Gansu Provincial People's Hospital, Lanzhou, China. 21. Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. 22. Division of Cardiology, Jiangxi Provincial People's Hospital, Nanchang, China. 23. Division of Cardiology, Anhui Provincial Hospital, Hefei, China. 24. Division of Cardiology, Tianjin 4th Central Hospital, Tianjin, China. 25. Division of Cardiology, Wuxi 3rd People's Hospital, Wuxi, China. 26. Division of Cardiology, Yixing People's Hospital, Yixing, China. 27. Division of Cardiology, Cheng-Hsin General Hospital, Taipei, China. 28. Division of Cardiology, Cangzhou Central Hospital, Cangzhou, China. 29. Division of Cardiology, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China. 30. Division of Cardiology, Jintan Traditional Chinese Medicine Hospital, Jintan, China. 31. Division of Cardiology, Liyang Hospital of Traditional Chinese Medicine, Liyang, China. 32. Division of Cardiology, Chuzhou People's Hospital, Chuzhou, China. 33. Division of Cardiology, Huaian 2nd People's Hospital, Huaian, China. 34. Division of Cardiology, Xinyang Central Hospital, Xinyang, China. 35. Division of Cardiology, Lianyungang Traditional Chinese Medicine Hospital, Lianyungang, China. 36. Division of Cardiology, XuanCheng Central Hospital, Xuancheng, China. 37. Division of Cardiology, Xuyi People's Hospital, Xuyi, China. 38. Division of Cardiology, Jintan People's Hospital, Jintan, China. 39. Division of Cardiology, Huainan People's Hospital, Huainan, China. 40. Division of Cardiology, 2nd People's Hospital, Shandong University, Jinan, China. 41. Division of Cardiology, Changzhou Traditional Chinese Medicine Hospital, China. 42. Division of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. 43. Division of Cardiology, Anqing 1st People's Hospital, Anqing, China. 44. Division of Cardiology, Changshu People's Hospital, Changshu, China. 45. Division of Cardiology, 17th Metallurgical Hospital, Maanshan, China. 46. Division of Cardiology, Qingdao Campus of Fuwai Hospital, Qingdao, China. 47. Division of Cardiology, Xuzhou 2nd People's Hospital, Xuzhou, China. 48. Division of Cardiology, Wuxi Huishan District People's Hospital, Wuxi, China. 49. Division of Cardiology, Nanjing 81 Hospital, Nanjing, China. 50. Division of Cardiology, Hongze People's Hospital, Huai'an, China. 51. Trinity College, University of Toronto, Toronto, Canada. 52. Mailman School of Public Health, Columbia University, New York, NY, USA. 53. The Zena and Michael A. Wiener Cardiovascular Institute, Ican School of Medicine at Mount Sinai, New York, NY, USA and The Cardiovascular Research Foundation, New York, NY, USA. 54. College of Pharmacy, Nanjing Medical University, Nanjing, China.
Abstract
AIM: The present study aimed to assess the benefits of two-stent techniques for patients with DEFINITION criteria-defined complex coronary bifurcation lesions. METHODS AND RESULTS: In total, 653 patients with complex bifurcation lesions at 49 international centres were randomly assigned to undergo the systematic two-stent technique (two-stent group) or provisional stenting (provisional group). The primary endpoint was the composite of target lesion failure (TLF) at the 1-year follow-up, including cardiac death, target vessel myocardial infarction (TVMI), and clinically driven target lesion revascularization (TLR). The safety endpoint was definite or probable stent thrombosis. At the 1-year follow-up, TLF occurred in 37 (11.4%) and 20 (6.1%) patients in the provisional and two-stent groups, respectively [77.8%: double-kissing crush; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.30-0.90; P = 0.019], largely driven by increased TVMI (7.1%, HR 0.43, 95% CI 0.20-0.90; P = 0.025) and clinically driven TLR (5.5%, HR 0.43, 95% CI 0.19-1.00; P = 0.049) in the provisional group. At the 1 year after indexed procedures, the incidence of cardiac death was 2.5% in the provisional group, non-significant to 2.1% in the two-stent group (HR 0.86, 95% CI 0.31-2.37; P = 0.772). CONCLUSION: For DEFINITION criteria-defined complex coronary bifurcation lesions, the systematic two-stent approach was associated with a significant improvement in clinical outcomes compared with the provisional stenting approach. Further study is urgently warranted to identify the mechanisms contributing to the increased rate of TVMI after provisional stenting. STUDY REGISTRATION: http://www.clinicaltrials.com; Identifier: NCT02284750. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIM: The present study aimed to assess the benefits of two-stent techniques for patients with DEFINITION criteria-defined complex coronary bifurcation lesions. METHODS AND RESULTS: In total, 653 patients with complex bifurcation lesions at 49 international centres were randomly assigned to undergo the systematic two-stent technique (two-stent group) or provisional stenting (provisional group). The primary endpoint was the composite of target lesion failure (TLF) at the 1-year follow-up, including cardiac death, target vessel myocardial infarction (TVMI), and clinically driven target lesion revascularization (TLR). The safety endpoint was definite or probable stent thrombosis. At the 1-year follow-up, TLF occurred in 37 (11.4%) and 20 (6.1%) patients in the provisional and two-stent groups, respectively [77.8%: double-kissing crush; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.30-0.90; P = 0.019], largely driven by increased TVMI (7.1%, HR 0.43, 95% CI 0.20-0.90; P = 0.025) and clinically driven TLR (5.5%, HR 0.43, 95% CI 0.19-1.00; P = 0.049) in the provisional group. At the 1 year after indexed procedures, the incidence of cardiac death was 2.5% in the provisional group, non-significant to 2.1% in the two-stent group (HR 0.86, 95% CI 0.31-2.37; P = 0.772). CONCLUSION: For DEFINITION criteria-defined complex coronary bifurcation lesions, the systematic two-stent approach was associated with a significant improvement in clinical outcomes compared with the provisional stenting approach. Further study is urgently warranted to identify the mechanisms contributing to the increased rate of TVMI after provisional stenting. STUDY REGISTRATION: http://www.clinicaltrials.com; Identifier: NCT02284750. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ilias Nikolakopoulos; Evangelia Vemmou; Judit Karacsonyi; Lorenzo Azzalini; Brian A Bergmark; Yiannis S Chatzizisis; Allison B Hall; Jason Wollmuth; Kevin Croce; Hani Jneid; Bavana V Rangan; M Nicholas Burke; Emmanouil S Brilakis Journal: J Invasive Cardiol Date: 2022-01 Impact factor: 2.022
Authors: Francesco Burzotta; Jens Flensted Lassen; Thierry Lefèvre; Adrian P Banning; Yiannis S Chatzizisis; Thomas William Johnson; Miroslaw Ferenc; Sudhir Rathore; Remo Albiero; Manuel Pan; Olivier Darremont; David Hildick-Smith; Alaide Chieffo; Marco Zimarino; Yves Louvard; Goran Stankovic Journal: EuroIntervention Date: 2021-03-19 Impact factor: 6.534